Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.75 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.75 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.75 |
| ▸ | LDHA | P00338 | 1/20 | 0.75 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.75 |
| ▸ | FBP1 | P09467 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.75 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.75 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.75 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.75 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.75 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275138 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL23647917 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL9990451 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL20942825 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29496215 | 0.96 | P2RY1 (0.80) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| Adenosine Phosphate SCHEMBL3828789 | 0.90 | P2RY1 (0.92) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL3694223 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 | |
| SCHEMBL25413594 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 | |
| SCHEMBL29796608 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 | |
| SCHEMBL3694227 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20250019719-A1 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-01-16 | — | — | US | claimed |
| US-20240279676-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-08-22 | — | — | US | claimed |
| EP-4347841-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-04-10 | — | — | EP | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| WO-2022247943-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2022-12-01 | — | — | WO | claimed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | MODERNATX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107055-A1 | HEPATITIS B VIRUS VACCINE AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIV OF PENNSYLVANIA (US) | 2026-05-21 | — | — | US | disclosed |
| CN-107949424-B | TAT-induced CRISPR/endonuclease-based gene editing | 天普大学-联邦高等教育系统 | 2022-03-01 | — | — | CN | disclosed |
| US-20220054525-A1 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-02-24 | — | — | US | disclosed |
| WO-2022032154-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| EP-3394093-B1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | LCP2, CD47, CD4 | ADORA1 3112/4885DNPH1 3747/4885PRKAB2 3836/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | ADORA1 4370/4885DNPH1 4665/4885PRKAB2 1696/4885 |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | ADORA1 4639/4885DNPH1 2573/4885PRKAB2 3423/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | ADORA1 16/4885DNPH1 3133/4885PRKAB2 1632/4885 |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | ELAVL1, IGF2BP2, FUS | ADORA1 2437/4885DNPH1 4723/4885PRKAB2 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.